A population-based gene signature is predictive of breast cancer survival and chemoresponse

International Journal of Oncology

Volumn 36, Issue 3, 2010, Pages 607-616

  Rathnagiriswaran, Shruti ^a   Wan, Ying Wooi ^a   Abraham, Jame ^a   Castranova, Vincent ^b   Qian, Yong ^b   Guo, Nancy L ^a,c  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer prognosis; Chemosensitivity prediction; Gene signature; NCI 60 cell lines

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MESSENGER RNA; METHOTREXATE; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; LYMPH NODE; OVERALL SURVIVAL; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; TUMOR GENE; ALGORITHM; BREAST NEOPLASMS; COHORT ANALYSIS; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MORTALITY; TREATMENT OUTCOME; TUMOR CELL LINE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 77149159441     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000536     Document Type: Article

References (38)

1. Peto R, Boreham J, Clarke M, Davies C and Beral V: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355: 1822, 2000.
2. Giordano SH, Buzdar AU, Smith TL, et al: Is breast cancer survival improving? Cancer 100: 44-52, 2004.
3. Schnitt SJ: Traditional and newer pathologic factors. J Natl Cancer Inst Monogr 30: 22-26, 2001.
4. Hayes DF, Isaacs C and Stearns V: Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 6: 375-392, 2001.
5. Bild AH, Yao G, Chang JT, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357, 2006.
6. Chang HY, Nuyten DS, Sneddon JB, et al: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102: 3738-3743, 2005.
7. Huang E, Cheng SH, Dressman H, et al: Gene expression predictors of breast cancer outcomes. Lancet 361: 1590-1596, 2003.
8. Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616, 2004.
9. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004.
10. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
11. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
12. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398, 2003.
13. van de Vijver MJ, He YD, van't Veer LJ, et al: A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002.
14. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679, 2005.
15. West M, Blanchette C, Dressman H, et al: Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98: 11462-11467, 2001.
16. Zhao H, Langerod A, Ji Y, et al: Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15: 2523-2536, 2004.
17. Miller LD, Smeds J, George J, et al: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102: 13550-13555, 2005.
18. Naderi A, Teschendorff AE, Barbosa-Morais NL, et al: A geneexpression signature to predict survival in breast cancer across independent data sets. Oncogene 26: 1507-1516, 2007.
19. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
20. Sjöström J: Predictive factors for response to chemotherapy in advanced breast cancer. Acta Oncol 41: 334-345, 2002.
21. Ma Y, Qian Y, Wei L, et al: Population-based molecular prognosis of breast Cancer by Transcriptional Profiling. Clin Cancer Res 13: 2014-2022, 2007.
22. Sawyers CL: The cancer biomarker problem. Nature 452: 548-552, 2008.
23. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.
24. Loi S, Haibe-Kains B, Desmedt C, et al: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25: 1239-1246, 2007.
25. Ivshina AV, George J, Senko O, et al: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292-10301, 2006.
26. Eick CF, Rouhana A, Bagherjeiran A and Vilalta R: Using clustering to learn distance functions for supervised similarity assessment. Eng Appl Artif Intell 19: 395-401, 2006.
27. Levner I: Feature selection and nearest centroid classification for protein mass spectrometry. BMC Bioinformatics 6: 68, 2005.
28. Strickert M, Schleif F-M, Villman T and Seiffert U: Unleashing Pearson Correlation for faithful analysis of biomedical data. In: Similarity-based Clustering. Springer, Berlin, pp70-91, 2009.
29. Weinstein JN, Myers TG, O'Connor PM, et al: An informationintensive approach to the molecular pharmacology of cancer. Science 275: 343-349, 1997.
30. Everitt B and Hothorn T (eds): A Handbook of Statistical Analyses Using R. Chapman and Hall/CRC, Boca Raton, FL 2006.
31. Shankavaram UT, Reinhold WC, Nishizuka S, et al: Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 6: 820-832, 2007.
32. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F and Spencer F: A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 99: 909, 2004.
33. Ma Y, Ding Z, Qian Y, et al: An integrative genomic and proteomic approach to chemosensitivity prediction. Int J Oncol 34: 107-115, 2009.
34. Ma Y, Ding Z, Qian Y, et al: Predicting cancer drug response by proteomic profiling. Clin Cancer Res 12: 4583-4589, 2006.
35. Witten IH and Frank E (eds): Data Mining: Practical Machine Learning Tools and Techniques. (2nd edition). Morgan Kaufmann, San Francisco, 2005.
36. Fan C, Oh DS, Wessels L, et al: Concordance among geneexpression-based predictors for breast cancer. N Engl J Med 355: 560-569, 2006.
37. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100: 229-235, 2006.
38. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK). Exp Oncol 28: 99-105, 2006.